Mission
Impact Stories
Medical Devices
Health Information Systems
Biotech Tools
Biopharmaceuticals
Back to the TOP
MedStars, an investment and executive management firm, has specialized over the last 25 years in starting and developing new life sciences companies with innovative products and services.

By providing access to seed capital and operational hands-on expertise, MedStars brings to early stage healthcare companies the financial and business expertise needed to get the companies off the ground. MedStars then helps these companies to prove technical and market feasibility, develop sound business models and attract permanent senior management in order to be further financed by venture firms or corporate partners.
MedStars reshaped the business strategy of a new breast cancer diagnostic start up to focus its new revolutionary ductal lavage procedure on high risk patients for early market acceptance. As a result, the company modified its product development and regulatory process and was successfully acquired two years later for over $167 Million.
MedStars refocused the product development and strategy of a new revolutionary brain monitoring company. The hands on implementation of the new business plan facilitated several rounds of venture capital, market leadership in the anesthesia market and an IPO in 2000.
MedStars turned around a drug dispensing start up by modifying the concept and product design to improve nursing satisfaction and decrease medication errors in hospitals. This led to the creation of a huge market, an IPO and an ultimate acquisition for $1 billion.
As active hands on advisor and then, founding VP of marketing, Anne De Gheest grew from zero to $50 million in three years a new early stage start up in automated point-of-use management systems for medical supplies. The company went public in 2001.
While consulting for scientists at the Stanford Medical School, MedStars developed a paradigm-shifting business model to commercialize a new robotic DNA synthesis technology. Dr. Molinari became the founding CEO of Protogene, which then grew into the world's largest supplier of custom DNA within its first 2 years, and generated over $10 million in liquid returns to its founders in that time.

MedStars wrote the founding business plan for one of the first DNA chip companies. Coining the phrase "electronic stringency control" to describe the benefit of this company's DNA chip analysis, the MedStars business plan was used to obtain the first round of funding from top tier venture investors. The company subsequently went public at a market cap of over $ 200 Million and is today the leading company in active matrix DNA chip technology.
MedStars developed a strategic plan for this company with pluronic coatings technology which delivered highly functional proteins on surfaces. After analyzing the market dynamics and product benefits, MedStars repositioned the company from reagents and protein chip businesses into a major technology provider to the cellular and tissue engineering markets. The MedStars report was then used as a strategic template to identify and hire a highly experienced management team which funded the company going forward according to the MedStars business strategy.
MedStars wrote a major "white paper" on the future of genomics and bioinformatics in the pharmaceutical industry and in society for the Institute for the Future. The paper explored such issues as what technologies were likely to become and remain important, who would access them, drive their development, and reap the rewards of consumer product demand, and what social issues were likely to impact the technologies. Many of the principles of the MedStars thesis were then incorporated into a major 2001 publication of the Institute entitled: "The Future of Pharmaceuticals".